ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +4.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 1.67M | $453.36M | n/a | n/a |
| Q2 2026 | 164 | +8 | 117.28M | $20.62B | +11 | −2 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | n/a | 22.19M | $2.32B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 18.90M | +4.8% | $1.50B | 0.2% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 5.85M | +1.0% | $464.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 3.01M | -0.2% | $238.88M | 0.2% | ▼ Trim | 4 | SEC ↗ ×4 |
| 4 | Geode Capital Management ✦ (passive) | 2.85M | +4.2% | $225.46M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | PRIMECAP Management ✦ | 2.37M | -3.5% | $188.11M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 2.12M | +361.7% | $165.48M | 0.2% | ▲ Add | 4 | SEC ↗ ×7 |
| 7 | Renaissance Technologies ✦ | 1.09M | +20.4% | $86.45M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | ARK Investment Management ✦ | 895.32K | +30.4% | $71.03M | 0.7% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 459.54K | -37.4% | $36.46M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 332.31K | -37.5% | $26.37M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 306.55K | +3530.4% | $24.32M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | Icahn Capital ✦ | 220.00K | +450.0% | $17.45M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 184.99K | +174.0% | $14.68M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 116.38K | +7.4% | $9.23M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 15 | D. E. Shaw & Co. ✦ | 75.16K | +115.1% | $5.96M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 16 | Norges Bank ✦ (passive) | 75.16K | -95.6% | $5.96M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 63.46K | +135.7% | $5.03M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Marshall Wace ✦ | 40.03K | New | $3.18M | 0.0% | New | 1 | SEC ↗ |
| 19 | Wellington Management ✦ | 37.21K | +47.1% | $2.95M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $3.18M | 0.0% |
Exited
| GAMCO Investors | $211,804 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 837 holders, 154.80M shares, $18.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 7.50K sh · $1.63M
Director · 11.35K sh · $2.49M
Director · 100.65K sh · $21.98M
Director · 13.26K sh · $2.87M
Director · 9.96K sh · $2.21M
Director · 6.66K sh · $1.47M
Director · 13.72K sh · $3.01M
Director · 9.72K sh · $2.12M
Director · 14.20K sh · $3.08M
Director · 8.44K sh · $1.82M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology